DABIGATRAN AND IDARUZIZUMAB. NEW OPPORTUNITIES FOR IMPROVING PATIENT SAFETY

The widespread use of new oral anticoagulants in clinical practice requires improving the safety of medication use, i.e. the use of specific reversal agents, if necessary. Idarucizumab, a humanied monoclonal antibody fragment, is the first reversal agent authorized in our country that binds to dabig...

Olles dieđut

Furkejuvvon:
Bibliográfalaš dieđut
Váldodahkkit: N. A. Novikova (Dahkki), A. N. Volovchenko (Dahkki), D. A. Parfenov (Dahkki)
Materiálatiipa: Girji
Almmustuhtton: «REMEDIUM GROUP» Ltd., 2019-06-01T00:00:00Z.
Fáttát:
Liŋkkat:Connect to this object online.
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Interneahtta

Connect to this object online.

3rd Floor Main Library

oažžasuvvan: 3rd Floor Main Library
Hildobáiki: A1234.567
Njađus 1 Oažžumis